ATE343792T1 - Diagnostika und therapeutika für maculare degeneration - Google Patents

Diagnostika und therapeutika für maculare degeneration

Info

Publication number
ATE343792T1
ATE343792T1 AT00915845T AT00915845T ATE343792T1 AT E343792 T1 ATE343792 T1 AT E343792T1 AT 00915845 T AT00915845 T AT 00915845T AT 00915845 T AT00915845 T AT 00915845T AT E343792 T1 ATE343792 T1 AT E343792T1
Authority
AT
Austria
Prior art keywords
macular degeneration
therapeutics
diagnostics
arterial wall
aneurysm
Prior art date
Application number
AT00915845T
Other languages
English (en)
Inventor
Gregory S Hageman
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Application granted granted Critical
Publication of ATE343792T1 publication Critical patent/ATE343792T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/16Ophthalmology
    • G01N2800/164Retinal disorders, e.g. retinopathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/329Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
AT00915845T 1999-02-19 2000-02-22 Diagnostika und therapeutika für maculare degeneration ATE343792T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12082299P 1999-02-19 1999-02-19
US12066899P 1999-02-19 1999-02-19
US12305299P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
ATE343792T1 true ATE343792T1 (de) 2006-11-15

Family

ID=27382498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00915845T ATE343792T1 (de) 1999-02-19 2000-02-22 Diagnostika und therapeutika für maculare degeneration

Country Status (6)

Country Link
EP (2) EP1153302B1 (de)
JP (2) JP2003506016A (de)
AT (1) ATE343792T1 (de)
AU (2) AU3704900A (de)
DE (1) DE60031512T2 (de)
WO (2) WO2001006262A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
DE10111925A1 (de) * 2001-03-13 2002-10-02 Ogham Gmbh Herzchip
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
EP1580553A4 (de) * 2002-11-29 2006-01-18 Eisai Co Ltd Verfahren zum testen eines elastinverdauungsprodukts und testkit, verfahren zum nachweis einer aortendissektion und nachweiskit
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
WO2005083430A1 (en) * 2004-02-25 2005-09-09 Massachusetts Eye & Ear Infirmary Biomarkers for age-related macular degeneration (amd)
US8088579B2 (en) * 2005-02-14 2012-01-03 University Of Iowa Research Foundation Complement factor H for diagnosis of age-related macular degeneration
EP1937706A4 (de) * 2005-09-09 2008-10-22 Univ Iowa Res Found Mit altersabhängiger makulardegeneration in zusammenhang stehende biologische marker
EP1996949A4 (de) * 2006-03-11 2010-01-20 Univ Leland Stanford Junior Beta-2 mikroglobulin als biomarker für periphere arterienerkrankung
WO2008008986A2 (en) 2006-07-13 2008-01-17 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
DK2140269T3 (da) 2007-03-27 2013-12-16 Immunovia Ab Proteinsignatur/markører til at detektere adenocarcinom
WO2009003142A1 (en) 2007-06-27 2008-12-31 The Board Of Trustees Of The Leland, Stanford Junior University Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease
EP2238455A4 (de) * 2008-01-18 2011-03-02 Vatrix Medical Inc Diagnostische biomarker für gefässaneurysma
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
EP2509596B1 (de) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminosäure zur behandlung von augenerkrankungen
WO2011083145A1 (en) * 2010-01-08 2011-07-14 Cavadis B.V. Determination of exosomel biomarkers for predicting cardiovascular events
WO2012040619A2 (en) 2010-09-24 2012-03-29 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
WO2014168154A1 (ja) * 2013-04-08 2014-10-16 三菱レイヨン株式会社 眼疾患を評価するためのマイクロアレイ及び眼疾患の評価方法
US10274503B2 (en) * 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
EP4257191A3 (de) 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclische prolinamidderivate
RU2681279C1 (ru) * 2018-04-11 2019-03-05 Анна Анатольевна Олейник Способ выявления разновидности формы множественных аневризм сосудов головного мозга в отдаленном послеоперационном периоде
WO2020190081A1 (ko) * 2019-03-20 2020-09-24 (주)레티마크 실명 유발 주요 안질환 진단용 혈액 마커 및 이를 이용한 진단 방법
AU2020295824A1 (en) * 2019-06-20 2022-01-20 Spring Vision Ltd. System and method for fluorescence imaging of biological tissues
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112156172B (zh) * 2020-10-26 2022-11-25 上海交通大学医学院附属第九人民医院 血小板反应蛋白1在制备预防和/或治疗年龄相关性黄斑变性的药物中的应用
CN112946274B (zh) * 2021-02-04 2024-03-26 复旦大学 颅内动脉瘤诊断血清标志物以及预测颅内动脉瘤破裂潜能血清标志物
CN115443947B (zh) * 2022-10-12 2023-11-21 江苏省人民医院(南京医科大学第一附属医院) 高血压动物模型的制备方法
CN115851909B (zh) * 2022-11-21 2023-09-08 郑州大学第一附属医院 检测fosb基因的试剂在制备诊断腹主动脉瘤产品的应用
CN116825346B (zh) * 2023-06-06 2026-03-27 中国人民解放军北部战区总医院 一种生物标志物组合在构建颅内动脉瘤破裂的预测模型中的应用
CN118580331B (zh) * 2024-08-06 2025-01-21 上海先赛生物科技有限公司 一种用于主动脉夹层检测的蛋白抗原组合及应用
CN121410078A (zh) * 2025-10-28 2026-01-27 鄂尔多斯应用技术学院 一种基于ii型异质结构建的新型pec传感器的制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9304075A (es) * 1992-07-08 1994-04-29 Applied Research Systems Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
WO1995017673A1 (en) * 1993-12-21 1995-06-29 Ocutech, Inc. Ocular diagnostics and therapies
JP2000509073A (ja) * 1996-05-02 2000-07-18 シェーリング コーポレイション 虚血再灌流傷害の治療または予防の方法

Also Published As

Publication number Publication date
WO2001006262A1 (en) 2001-01-25
EP1153302A1 (de) 2001-11-14
JP2003504088A (ja) 2003-02-04
AU3704500A (en) 2001-01-22
AU3704900A (en) 2001-02-05
JP2003506016A (ja) 2003-02-18
EP1153301A1 (de) 2001-11-14
DE60031512T2 (de) 2007-08-23
WO2001002866A1 (en) 2001-01-11
DE60031512D1 (de) 2006-12-07
EP1153302B1 (de) 2006-10-25

Similar Documents

Publication Publication Date Title
DE60031512D1 (de) Diagnostika und therapeutika für maculare degeneration
DE60136272D1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
WO2000072015A3 (en) Diagnostics and therapeutics for cardiovascular disorders
ATE290375T1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
TW200642694A (en) Anti-M-CSF antibody compositions
MA29528B1 (fr) Agents de fixation
DE69519929D1 (de) Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
ATE424560T1 (de) Marker für neuromyelitis optica
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ATE460802T1 (de) Ermöglichung der gleichzeitigen benutzung eines heimatnetzes und fremdnetzes durch einen mehrfachheimat-mobilknoten
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
WO2006023412A3 (en) Biomarkers for osteoarthritis
DE60125681D1 (de) Verwendung von NMDA NR2B Antagonist zur Behandlung von Depressionen.
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
ATE525976T1 (de) Befestigung für einen stent-graft
DE50101479D1 (de) Fluoresceinisothiocyanat-(fitc)-sinistrin, seine herstellung und verwendung
DE69934983D1 (de) Verfahren, vorrichtung und bildgebungsmodus für tomographische bildgebung
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
MXPA02011516A (es) Modelo de animal transgenico de trastornos neurodegenerativos.
DE60136170D1 (de) Einen nmda rezeptor enthaltende multiprotein-komplexe und deren verwendung
ATE504863T1 (de) Nichtmagnetische einkomponentige tonerzusammensetzung, verfahren zu ihrer herstellung, und gebrauch
MX2009005793A (es) Marcadores farmacodinamicos inducidos por interferon alfa.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties